These results indicated that ibrutinib might be a potential drug candidate for the EGFR (L858R, del19) mutant driven NSCLC and a useful candidate for combinatorial therapy aimed at overcoming (L858R/T790M) resistance in NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.